Related Experiment Video
Updated: Nov 22, 2025

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Cerebrovascular and Neurodegenerative Pathologies in Long-Term Stable Mild Cognitive Impairment
Manu J Sharma1,2, Brandy L Callahan1,2
1Department of Psychology, University of Calgary, Calgary (AB), Canada.
Background:
Mild cognitive impairment (MCI) is considered by some to be a prodromal phase of a progressive disease (i.e., neurodegeneration) resulting in dementia; however, a substantial portion of individuals (ranging from 5-30%) remain cognitively stable over the long term (sMCI). The etiology of sMCI is unclear but may be linked to cerebrovascular disease (CVD), as evidence from longitudinal studies suggest a significant proportion of individuals with vasculopathy remain stable over time.
Objective:
To quantify the presence of neurodegenerative and vascular pathologies in individuals with long-term (>5-year) sMCI, in a preliminary test of the hypothesis that CVD may be a contributor to non-degenerative cognitive impairment. We expect frequent vasculopathy at autopsy in sMCI relative to neurodegenerative disease, and relative to individuals who convert to dementia.
Methods:
In this retrospective study, using data from the National Alzheimer's Coordinating Center, individuals with sMCI (n = 28) were compared to those with MCI who declined over a 5 to 9-year period (dMCI; n = 139) on measures of neurodegenerative pathology (i.e., Aβ plaques, neurofibrillary tangles, TDP-43, and cerebral amyloid angiopathy) and CVD (infarcts, lacunes, microinfarcts, hemorrhages, and microbleeds).
Results:
Alzheimer's disease pathology (Aβ plaques, neurofibrillary tangles, and cerebral amyloid angiopathy) was significantly higher in the dMCI group than the sMCI group. Microinfarcts were the only vasculopathy associated with group membership; these were more frequent in sMCI.
Conclusion:
The most frequent neuropathology in this sample of long-term sMCI was microinfarcts, tentatively suggesting that silent small vessel disease may characterize non-worsening cognitive impairment.
Insights
Stable mild cognitive impairment (sMCI) may be characterized by cerebrovascular disease (CVD), specifically microinfarcts. This contrasts with progressive MCI, which shows more Alzheimer's disease pathology.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- Mild cognitive impairment (MCI) can be a precursor to dementia, but a significant subset (5-30%) remains stable long-term (sMCI).
- The causes of sMCI are not fully understood but may involve cerebrovascular disease (CVD), as some individuals with vasculopathy do not progress.
Purpose of the Study:
- To investigate the neuropathological differences between long-term stable MCI (sMCI) and MCI that progresses to dementia (dMCI).
- To test the hypothesis that CVD contributes to non-progressive cognitive impairment.
Main Methods:
- A retrospective analysis of autopsy data from the National Alzheimer's Coordinating Center.
- Comparison of neurodegenerative markers (Aβ plaques, tangles, TDP-43, CAA) and CVD markers (infarcts, lacunes, microinfarcts, hemorrhages, microbleeds) in sMCI (n=28) and dMCI (n=139) groups.
Main Results:
- Alzheimer's disease pathologies were more prevalent in the dMCI group compared to the sMCI group.
- Microinfarcts were the only identified vasculopathy linked to group status, appearing more frequently in the sMCI group.
Conclusions:
- Microinfarcts were the most common neuropathology found in long-term sMCI cases.
- These findings suggest that silent small vessel disease might be a characteristic feature of non-worsening cognitive impairment.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Cognitive Development During Adulthood
Long-term Depression
Calcium Ion Concentration Mechanism
If over...
Long-term Depression
Dementia
The progression of dementia is generally gradual....
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

